39 / 84
279
Ces Urol 2015; 19(4): 270–280
PŘEHLEDOVÝ ČLÁNEK
20. Hatina J, Kripnerová M, Matoušková E.
Orgánové, organotypické a trojrozměrné kultury. Výukový
portál Lékařské fakulty v Plzni [online] 28.1.2015, poslední aktualizace 9. 3. 2015 [cit. 2015-06-30] Dostupný
z WWW: <http://mefanet.lfp.cuni.cz/clanky.php?aid=441>. ISSN 1804-4409.
21. Earl J, Rico D, Carrillo-de-Santa-Pau E, et al.
The UBC-40 Urothelial Bladder Cancer cell line index:
a genomic resource for functional studies. BMC Genomics 2015 May; 16(1): 403.
22. Seifert HH, Meyer A, Cronauer MV, et al.
A new and reliable culture system for superficial low-grade
urothelial carcinoma of the bladder. World J Urol. 2007 Jun; 25(3): 297–302.
23. Koch A, Hatina J, Rieder H, et al.
Discovery of TP53 splice variants in two novel papillary urothelial
cancer cell lines. Cell Oncol (Dordr) 2012 Aug; 35(4): 243–257.
24. Hatina J, Kripnerova M, Tukova J, et al.
Tumor-Stroma Interaktionen im Harnblasenkarzinom. Urologe
2015; 54: 516–525.
25. Hatina J, Ruzicka T.
Stellenwert der Zellkulturmodelle in kutaner Tumorbiologie. Teil I: Zelllinien tumo‑
rigen transformierter Zellen. Hautarzt. 2008 Jan; 59(1): 36–45.
26. Sarkar S, Jülicher KP, Burger MS, et al.
Different combinations of genetic/epigenetic alterations inactiva‑
te the p53 and pRb pathways in invasive human bladder cancers. Cancer Res 2000 Jul 15; 60(14): 3862–3871.
27. Hatina J, Huckenbeck W, Rieder H, Seifert HH, Schulz WA.
Harnblasenkarzinomzelllinien als Modellsys‑
teme zur Pathobiologie des Harnblasenkarzinoms. Überblick und Etablierung einer neuen Progressionsserie.
Urologe A 2008 Jun; 47(6): 724–734.
28. Bubenik J, Baresova M, Viklicky V, et al.
Established cell line of urinary bladder carcinoma (T24) con‑
taining tumour-specific antigen. Int J Cancer 1973 May; 11(3): 765–773.
29. Gildea JJ, Golden WL, Harding MA, Theodorescu D.
Genetic and phenotypic changes associated
with the acquisition of tumorigenicity in human bladder cancer. Genes Chromosomes Cancer 2000 Mar;
27(3): 252–63.
30. Wu Y, McRoberts K, Berr SS, et al.
Neuromedin U is regulated by the metastasis suppressor RhoGDI2
and is a novel promoter of tumor formation, lung metastasis and cancer cachexia. Oncogene 2007 Feb
1; 26(5): 765–773.
31. Chaffer CL, Brennan JP, Slavin JL, et al.
Mesenchymal-to-epithelial transition facilitates bladder cancer
metastasis: role of fibroblast growth factor receptor-2. Cancer Res 2006 Dec; 66(23): 11271–11278.
32. Makridakis M, Gagos S, Petrolekas A, et al.
Chromosomal and proteome analysis of a new T24-based
cell line model for aggressive bladder cancer. Proteomics 2009 Jan; 97–98.
33. Karam JA, Huang S, Fan J, et al.
Upregulation of TRAG3 gene in urothelial carcinoma of the bladder.
Int J Cancer 2011 Jun; 128(12): 2823–2832.
34. Moscow JA, Schneider E, Sikic BI, Morrow CS, Cowan KH.
Drug resistance and its clinical circumven‑
tion. In: Holland JF, Frei E, eds. Cancer Medicine. 8. ed. Shelton: PMPH-USA; 2010: 597–610.
35. Bambury RM, Rosenberg JE.
Advanced urothelial carcinoma: overcoming treatment resistance through
novel treatment approaches. Front Pharmacol 2013 Feb; 4: 1–7.
36. Seemann O, Muscheck M, Siegsmund M, et al.
Establishnent and characterization of a multidrug‑
-resistant human bladder carcinoma cell line RT112/D21. Urol Res 1995; 22: 353–360.
37. Usansky JI, Liebert M, Wedemeyer G, Grossman HB, Wagner JG.
The uptake and efflux of doxoru‑
bicin by a sensitive human bladder cancer cell line and its doxorubicin-resistant subline. Sel Cancer Ther
1991 Winter; 7(4): 139–150.
38. Tanaka M, Grossman HB.
In vivo gene therapy of human bladder cancer with PTEN suppresses tumor
growth, downregulates phosphorylated Akt, and increases sensitivity to doxorubicin. Gene Ther 2003 Sep;
10(19): 1636–1642.
39. Hong JH, Lee E, Hong J, Shin YJ, Ahn H.
Antisense Bcl2 oligonucleotide in cisplatin-resistant bladder
cancer cell lines. BJU Int 2002 Jul; 90(1): 113–117.